We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
-11.87%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.29B
AUM Growth
-$271M
(-17%)
Cap. Flow
-$42.3M
Cap. Flow
% of AUM
-3.27%
Top 10 Holdings %
Top 10 Hldgs %
80.94%
Holding
37
New
–
Increased
7
Reduced
17
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$2.63M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$2.1M |
| 3 |
Karyopharm Therapeutics
KPTI
|
+$1.26M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$935K |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$703K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$7.58M |
| 2 |
United Therapeutics
UTHR
|
+$6.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$6.14M |
| 4 |
Align Technology
ALGN
|
+$5.4M |
| 5 |
Biogen
BIIB
|
+$5.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.39% |
| 2 | Financials | 1.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$13.5B
| $165M | 12.75% |
2,139,614
-73,336
| -3% | -$6.14M |
|
|
ABMD
2
DELISTED
Abiomed Inc
ABMD
| $164M | 12.66% |
494,397
-24,636
| -5% | -$7.58M |
|
3
Insmed
INSM
$29B
| $138M | 10.69% |
5,881,299
-144,407
| -2% | -$3.36M |
|
|
4
United Therapeutics
UTHR
$22.1B
| $117M | 9.06% |
653,079
-34,127
| -5% | -$6.5M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $93.8M | 7.25% |
9,903,761
-210,282
| -2% | -$1.97M |
|
6
STAAR Surgical
STAA
$1.24B
| $90.9M | 7.02% |
1,136,968
-3,543
| -0.3% | -$264K |
|
|
RVNC
7
DELISTED
Revance Therapeutics, Inc.
RVNC
| $86.1M | 6.66% |
4,415,689
+46,323
| +1% | +$703K |
|
|
8
Biogen
BIIB
$30.1B
| $76M | 5.88% |
360,981
-24,019
| -6% | -$5.22M |
|
9
Prothena Corp
PRTA
$473M
| $61.5M | 4.75% |
1,681,477
-3,805
| -0.2% | -$137K |
|
10
Acadia Pharmaceuticals
ACAD
$5.07B
| $54.5M | 4.22% |
2,251,834
-86,043
| -4% | -$2.08M |
|
|
11
Karyopharm Therapeutics
KPTI
$47.6M
| $41.4M | 3.2% |
374,769
+10,072
| +3% | +$1.26M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $28.2M | 2.18% |
851,719
+69,989
| +9% | +$2.63M |
|
13
Vanda Pharmaceuticals
VNDA
$298M
| $28.2M | 2.18% |
2,491,200
-343,044
| -12% | -$4.51M |
|
14
eHealth
EHTH
$39.1M
| $20.5M | 1.59% |
1,652,260
+36,690
| +2% | +$632K |
|
|
15
Align Technology
ALGN
$12.3B
| $19.3M | 1.49% |
44,305
-11,100
| -20% | -$5.4M |
|
16
Alkermes
ALKS
$8.26B
| $17.7M | 1.37% |
673,571
-80,629
| -11% | -$2M |
|
17
Gossamer Bio
GOSS
$88.9M
| $15.2M | 1.18% |
1,756,757
-16,193
| -0.9% | -$156K |
|
|
KZR
18
DELISTED
Kezar Life Sciences
KZR
| $10.9M | 0.84% |
65,620
| – | – |
|
19
AnaptysBio
ANAB
$1.71B
| $10.7M | 0.82% |
431,024
-5,568
| -1% | -$169K |
|
20
Syndax Pharmaceuticals
SNDX
$1.81B
| $10.6M | 0.82% |
612,600
+13,700
| +2% | +$231K |
|
|
GRTS
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $9.6M | 0.74% |
2,330,504
-25,778
| -1% | -$137K |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.04M | 0.7% |
4,473,967
+476,141
| +12% | +$935K |
|
|
EPZM
23
DELISTED
Epizyme, Inc
EPZM
| $7.79M | 0.6% |
6,774,541
+1,289,328
| +24% | +$2.1M |
|
24
Travere Therapeutics
TVTX
$5.68B
| $4.28M | 0.33% |
166,069
| – | – |
|
25
Cytokinetics
CYTK
$10.6B
| $4.11M | 0.32% |
111,717
-11,969
| -10% | -$425K |
|
Similar funds
RRA
AG
BL
CG
GAMA
PIM
ACA
RK
Palo Alto Investors's Q1 2022 Portfolio in Review
As of Q1 2022, Palo Alto Investors held 37 positions worth $1.29B, down 17% from $1.56B the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Palo Alto Investors withdrew a net $42.3M in Q1 2022, closing 2 positions and reducing 17 holdings. Its most notable exit was Zogenix, Inc., an estimated $2.99M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.
Against the trend, Palo Alto Investors added an estimated $2.63M to Sage Therapeutics.
- Palo Alto Investors added most to Sage Therapeutics in Q1 2022, an estimated $2.63M increase.
- Palo Alto Investors's biggest Q1 2022 reduction was Abiomed Inc, cutting an estimated $7.58M.
- Palo Alto Investors fully exited Zogenix, Inc. in Q1 2022, selling an estimated $2.99M.
- Palo Alto Investors's ten largest holdings make up 81% of its $1.29B portfolio in Q1 2022.
- Palo Alto Investors opened 0 new positions and closed 2 in Q1 2022.
- Palo Alto Investors's portfolio value fell 17% quarter-over-quarter to $1.29B.
Based on Palo Alto Investors's 13F filing for Q1 2022, filed 16 May 2022.